Markets · 1 sources covering this

Lalithaa Jewellery Mart shares surge 36% from IPO price after strong market debut. Should you buy, sell or hold?

Lalithaa Jewellery Mart shares surged after debuting at a 32% premium to the IPO price, reaching over 36% gains. Strong subscription, attractive valuations versus peers and expansion plans have supported investor optimism. Analysts, however, caution about gold-price volatility, working-capital intensity, inventory management and consumer demand while offering mixed hold or profit-booking strategies.

Share:WhatsApp X Reddit Facebook

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

Economic TimesLean R·1h ago
Lalithaa Jewellery Mart shares surge 36% from IPO price after strong market debut. Should you buy, sell or hold?
Lalithaa Jewellery Mart shares surged after debuting at a 32% premium to the IPO price, reaching over 36% gains. Strong subscription, attractive valuations versus peers and expansion plans have supported investor optimism. Analysts, however, caution about gold-price volatility, working-capital intensity, inventory management and consumer demand while offering mixed hold or profit-booking strategies.
Read at Economic Times →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/abb906853dd6b0cb6b6c4abe3db86f4387572543"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Lalithaa Jewellery Mart shares surge 36% from IPO price after strong market debut. Should you buy, sell or hold?"></iframe>

Lalithaa Jewellery Mart shares surge 36% from IPO price after strong market debut. Should you buy, sell or hold?

How 1 sources are covering this

Lalithaa Jewellery Mart shares surge 36% from IPO price after strong market debut. Should you buy, sell or hold?

More from Markets

Small-cap IT stock under ₹50 jumps 5% after implementation of SpaceX International agreement plan

Avaada said to plan public filing for $800 million IPO

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

Madhur Knit Crafts, ABH Healthcare SME IPOs Day 1: Early subscription, GMP, and key details

Reader

Trust & legal

Across the network